抗HIV治療ガイドライン（2025年3月発行）

XIIHIV/HBV共感染者での抗HIV療法

文献

  1. Soriano V, Puoati M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22:1399-1410, 2008.
  2. Koike K, Kikuchi Y, Kato M, et al. Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res 38:310-314, 2008.
  3. Mizushima D, Takano M, Aoki T, et al. Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men. Hepatology. 77:2084-2092, 2023.
  4. Puoti M, Torti C, Bruno R. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44:65-70, 2006.
  5. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 18:2285-2293, 2004.
  6. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liverrelated mortality in the multicenter cohort Study (MACS), Lancet 360: 1921-26, 2002.
  7. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (米国DHHS, Sep 12, 2024).
    https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new
  8. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV, (米国DHHS, Dec. 16, 2024)
    https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
  9. European AIDS Clinical Society (EACS) Guidelines. Version 12.1-November 2024. https://eacs.sanfordguide.com
  10. Terrault NA, Lok ASF, Mcmahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatiology 67: 1560-1599, 2018.
  11. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 67:370-398, 2017.
  12. 日本肝臓学会肝炎診療ガイドライン作成委員会：B型肝炎治療ガイドライン（第4版）2022年6月
  13. Peters MG. Diagnosis and management of hepatitis B virus and HIV coinfection, Top HIV Med. 15:163-166, 2007.
  14. Gallant J, Brunetta J, Crofoot G, et al. Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-1/hepatitis B-coinfected adults. J Acquir Immune Defic Syndr. 73: 294-298, 2016.
  15. Avihingsanon A, Lu H, Leong CL, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. Lancet HIV. 10: e640-e652, 2023.
  16. Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection, AIDS 20:1951-1954, 2006.
  17. Kim HN, Newcomb CW, Carbonari DM, et al. Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America. Hepatology. 74: 1190–1202, 2021.
  18. Surial B, Mena AR, Roumet M, et al. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection. J Hepatol. 78: 947-957, 2023.
  19. 坪内博仁, 熊田博光, 清澤研道, 他. 免疫抑制・化学療法により発症するB型肝炎対策－厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告－. 肝臓 50: 38-42, 2009.
  20. 坪内博仁, 熊田博光, 清澤研道, 他. 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン（改訂版）：厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班. 2011.
  21. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 24:211-217, 2000.
  22. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 18:2039-2045, 2004.
  23. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75:347-354, 1998.
  24. Collins JM, Raphael KL, Terry C, et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus with Sofosbuvir and Simeprevir. Clin Infect Dis. 61:1304-6, 2015.
  25. Takayama H, Sato T, Ikeda F, et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 46:489-91, 2015.
  26. De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 78:27-30, 2016.
  27. Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 164:28;9, 2015.

PAGE TOP